• Home
  •  / Pulse Biosciences

Pulse Biosciences

OverviewSuggest Edit

Pulse Biosciences is a medical technology company developing a novel tissue treatment platform based on its proprietary Nano-Pulse Stimulation technology. Nano-Pulse Stimulation is a non-thermal, precise, focal drug-free tissue treatment technology that initiates cell death within treated tissue. NPS utilizes nanosecond pulsed electric fields to induce cell signaling and the activation of cellular pathways by creating transient nanopores in cellular membranes and organelles. Once created, these transient nanopores allow ions to pass through these membranes, which disrupts cellular function and initiates cell death. NPS cell death eliminates treated tissue cells with a minimal inflammatory response, leading to a favorable healing process and the replacement of treated tissue cells with healthy tissue cells.

TypePublic
Founded2014
HQHayward, CA, USMap
Websitepulsebiosciences.com
Overall CultureA+More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)82(+52%)
Share Price (Jan 2021)$29.5 (+3%)
Cybersecurity ratingAMore

Key People/Management at Pulse Biosciences

Darrin R. Uecker

Darrin R. Uecker

Chief Executive Officer, President & Director
Kenneth A. Clark

Kenneth A. Clark

Director
Ed Ebbers

Ed Ebbers

Executive Vice President and General Manager, Dermatology
Richard Nuccitelli

Richard Nuccitelli

Chief Science Officer
Sandra A. Gardiner

Sandra A. Gardiner

Executive Vice President and Chief Financial Officer
David Danitz

David Danitz

Vice President of Engineering
Show more

Pulse Biosciences Office Locations

Pulse Biosciences has an office in Hayward
Hayward, CA, US (HQ)
3957 Point Eden Way
Show all (1)

Pulse Biosciences Financials and Metrics

Pulse Biosciences Revenue

USD

Net income (Q2, 2020)

(11.3m)

Market capitalization (22-Jan-2021)

748.3m

Closing stock price (22-Jan-2021)

29.5

Cash (30-Jun-2020)

37.8m

EV

722.0m
Pulse Biosciences's current market capitalization is $748.3 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cost of goods sold

600.0k600.0k

General and administrative expense

2.9m15.5m20.0m22.3m

R&D expense

6.0m9.6m17.3m25.0m

Operating expense total

8.9m25.1m37.3m47.3m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

General and administrative expense

528.0k642.0k893.0k1.2m3.8m4.2m5.4m5.2m5.7m4.4m5.1m5.6m5.6m5.3m

R&D expense

990.0k1.5m1.7m1.9m2.3m3.2m3.2m4.0m5.0m5.8m6.3m6.2m6.2m5.9m

Operating expense total

1.5m2.1m2.6m3.1m6.1m7.4m8.6m9.1m10.7m10.2m11.5m11.8m11.8m11.2m

Depreciation and amortization

166.0k166.0k166.0k166.0k167.0k166.0k166.0k167.0k166.0k167.0k166.0k166.0k166.0k167.0k
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.1m3.4m51.1m6.9m

Prepaid Expenses

412.0k779.0k1.0m

Inventories

268.0k

Current Assets

16.7m38.5m60.4m26.4m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

2.1m20.2m4.6m2.8m2.0m32.4m10.7m6.8m6.3m8.5m10.8m9.6m7.9m37.8m

Prepaid Expenses

47.0k337.0k294.0k253.0k717.0k512.0k368.0k1.2m1.1m550.0k1.9m1.4m545.0k907.0k

Current Assets

2.6m21.0m19.0m19.1m16.1m42.6m33.7m28.7m22.1m53.4m44.6m35.9m16.4m38.7m

PP&E

346.0k344.0k323.0k293.0k2.7m2.6m2.5m2.4m2.3m2.1m2.0m2.4m2.6m2.6m
show all
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.8b)(25.6m)(37.5m)(47.0m)

Depreciation and Amortization

167.0m1.0m1.3m1.2m

Inventories

12.0k

Accounts Payable

29.0k517.0k490.0k646.0k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(1.7m)(3.9m)(6.7m)(3.2m)(9.4m)(16.9m)(8.7m)(17.8m)(28.6m)(10.1m)(21.4m)(33.2m)(11.9m)(23.2m)

Depreciation and Amortization

188.0k378.0k569.0k190.0k382.0k695.0k319.0k642.0k973.0k329.0k633.0k890.0k270.0k546.0k

Accounts Payable

34.0k71.0k184.0k517.0k586.0k649.0k162.0k720.0k499.0k(72.0k)305.0k544.0k(749.0k)(758.0k)

Cash From Operating Activities

(1.5m)(3.8m)(5.7m)(2.5m)(3.7m)(7.1m)(5.0m)(10.7m)(17.6m)(7.3m)(17.0m)(25.0m)(9.6m)(17.6m)
show all
USDQ1, 2016

Financial Leverage

1.1 x
Show all financial metrics

Pulse Biosciences Operating Metrics

FY, 2016

Patent Applications

61

Patents Issued

49
Show all operating metrics

Pulse Biosciences Cybersecurity Score

Cybersecurity ratingPremium dataset

A

90/100

Learn more about our premium products
SecurityScorecard logo

Pulse Biosciences Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Pulse Biosciences Online and Social Media Presence

Pulse Biosciences's Trends

Embed Graph

Pulse Biosciences Company Culture

  • Overall Culture

    A+

    95/100

  • CEO Rating

    A+

    100/100

  • Compensation

    A+

    100/100

Learn more on Comparably

Pulse Biosciences News and Updates

May 11, 2018

Pulse Biosciences' (PLSE) CEO Darrin Uecker on Q1 2018 Results - Earnings Call Transcript

Pulse Biosciences Blogs

January 25, 2021

Pulse Biosciences Announces CE Mark Approval for CellFX® System

- CellFX System Delivers Nano-Pulse Stimulation Technology to Clear Hard-to-Treat Benign Skin Lesions - First CellFX System Shipment Scheduled to Commence Controlled Launch Program with Clinical Aesthetic Experts in the European Union HAYWARD, Calif. --(BUSINESS WIRE)--Jan.
January 12, 2021

Pulse Biosciences Updates on CellFX System Regulatory and Clinical Study Progress

HAYWARD, Calif. --(BUSINESS WIRE)--Jan. 12, 2021-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or the “Company”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation™ (NPS™) technology, today announced CellFX ® System regulatory progress updates.
January 05, 2021

Pulse Biosciences, Inc. Announces Redemption of Warrants

HAYWARD, Calif. --(BUSINESS WIRE)--Jan. 5, 2021-- Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a novel bioelectric medicine company progressing Nano-Pulse Stimulation TM (NPS™) technology, announced today that on December 31, 2020 , it delivered a notice of
December 04, 2020

Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference

Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices and Aesthetic Dermatology Conference Content Import Fri, 12/04/2020 - 08:01 Pulse Biosciences Presents Update on Nano-Pulse Stimulation™ Technology at Prestigous Energy-Based Devices …
November 25, 2020

NEWS ARTICLE: Nano-pulse stimulation shows positive results

NEWS ARTICLE: Nano-pulse stimulation shows positive results renanjeff.lila… Wed, 11/25/2020 - 16:23 NEWS ARTICLE: Nano-pulse stimulation shows positive results 10/23/20 This release is a backfill from a News Wire News …
November 25, 2020

NEWS ARTICLE: Pulse Biosciences Presents Data on NPS Technology for Skin Lesions

NEWS ARTICLE: Pulse Biosciences Presents Data on NPS Technology for Skin Lesions renanjeff.lila… Wed, 11/25/2020 - 16:05 NEWS ARTICLE: Pulse Biosciences Presents Data on NPS Technology for Skin Lesions 10/19/20 This release is a backfill from a News Wire …
Show more

 Pulse Biosciences Frequently Asked Questions

  • When was Pulse Biosciences founded?

    Pulse Biosciences was founded in 2014.

  • Who are Pulse Biosciences key executives?

    Pulse Biosciences's key executives are Darrin R. Uecker, Kenneth A. Clark and Ed Ebbers.

  • How many employees does Pulse Biosciences have?

    Pulse Biosciences has 82 employees.

  • Who are Pulse Biosciences competitors?

    Competitors of Pulse Biosciences include Nurami Medical, Tethis and Stem Cell & Device Laboratory.

  • Where is Pulse Biosciences headquarters?

    Pulse Biosciences headquarters is located at 3957 Point Eden Way, Hayward.

  • Where are Pulse Biosciences offices?

    Pulse Biosciences has an office in Hayward.

  • How many offices does Pulse Biosciences have?

    Pulse Biosciences has 1 office.